Revenue: As of FY2025 Q2, the actual value is USD 1.34 B, missing the estimate of USD 1.348 B.EPS: As of FY2025 Q2, the actual value is USD 0.32, beating the estimate of USD 0.2474.EBIT: As of FY2025 Q2, the actual value is USD 86.53 M.<h3>Critical Illness Recovery Hospital Segment</h3><ul><li>Revenue: $601.1 million for Q2 2025, a decrease from $604.9 million in Q2 2024, primarily due to a decrease in revenue per patient day from $2,159 to $2,148.</li><li>Adjusted EBITDA: $56.3 million for Q2 2025, down from $71.8 million in Q2 2024, with a margin of 9.4% compared to 11.9%.</li></ul><h3>Rehabilitation Hospital Segment</h3><ul><li>Revenue: Increased by 17.2% to $313.8 million for Q2 2025 from $267.8 million in Q2 2024, driven by a 7.6% increase in patient days and a 5.8% increase in revenue per patient day.</li><li>Adjusted EBITDA: $71.0 million for Q2 2025, up from $62.0 million in Q2 2024, with a margin of 22.6% compared to 23.1%.</li></ul><h3>Outpatient Rehabilitation Segment</h3><ul><li>Revenue: Increased by 3.8% to $327.6 million for Q2 2025 from $315.5 million in Q2 2024, with patient visits increasing by 3.8%.</li><li>Adjusted EBITDA: $30.5 million for Q2 2025, up from $28.8 million in Q2 2024, with a margin of 9.3% compared to 9.1%.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $106.8 million for the six months ended June 30, 2025, down from $211.5 million for the same period in 2024, primarily due to the spin-off of Concentra.</li><li>Investing Activities: Used $117.0 million for the six months ended June 30, 2025, mainly for property and equipment purchases.</li><li>Financing Activities: Provided $2.8 million for the six months ended June 30, 2025, with significant cash used for stock repurchases and dividends.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue expanding its operations through new joint ventures and opening new outpatient rehabilitation clinics in existing markets to leverage existing referral relationships and brand awareness.</li><li>Non-Core Business: The company completed the spin-off of Concentra in 2024, which is now presented as discontinued operations.</li></ul>

Select Medical | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.34 B